Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG

Camrelizumab

Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.

Trial Locations (1)

RECRUITING

Sanbo Brain Hospital Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Sanbo Brain Hospital

OTHER